These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

299 related items for PubMed ID: 19095418

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unit.
    Mouton JW, Punt N, Vinks AA.
    Clin Ther; 2005 Jun; 27(6):762-72. PubMed ID: 16117983
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Pharmacodynamics of doripenem in critically ill patients with ventilator-associated Gram-negative bacilli pneumonia.
    Jaruratanasirikul S, Wongpoowarak W, Kositpantawong N, Aeinlang N, Jullangkoon M.
    Int J Antimicrob Agents; 2012 Nov; 40(5):434-9. PubMed ID: 22959555
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics of doripenem in infected patients treated within and outside the intensive care unit.
    Bhalodi AA, Keel RA, Quintiliani R, Lodise TP, Nicolau DP, Kuti JL.
    Ann Pharmacother; 2013 May; 47(5):617-27. PubMed ID: 23585647
    [Abstract] [Full Text] [Related]

  • 10. Population pharmacokinetic modeling and Monte Carlo simulation of varying doses of intravenous metronidazole.
    Sprandel KA, Drusano GL, Hecht DW, Rotschafer JC, Danziger LH, Rodvold KA.
    Diagn Microbiol Infect Dis; 2006 Aug; 55(4):303-9. PubMed ID: 16887471
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory].
    Sumitani Y, Kobayashi Y.
    Jpn J Antibiot; 2007 Dec; 60(6):394-403. PubMed ID: 18447209
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients.
    Samtani MN, Flamm R, Kaniga K, Nandy P.
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2360-4. PubMed ID: 20385857
    [Abstract] [Full Text] [Related]

  • 16. The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints.
    Stass H, Dalhoff A.
    Infection; 2005 Dec; 33 Suppl 2():29-35. PubMed ID: 16518709
    [Abstract] [Full Text] [Related]

  • 17. Steady-state pharmacokinetics and pharmacodynamics of cefepime administered by prolonged infusion in hospitalised patients.
    Cheatham SC, Shea KM, Healy DP, Humphrey ML, Fleming MR, Wack MF, Smith DW, Sowinski KM, Kays MB.
    Int J Antimicrob Agents; 2011 Jan; 37(1):46-50. PubMed ID: 21074370
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Pharmacokinetic-pharmacodynamic target attainment analysis of cefozopran in Japanese adult patients.
    Ikawa K, Nomura K, Morikawa N, Ikeda K, Ohge H, Sueda T, Taniwaki M.
    J Infect Chemother; 2008 Apr; 14(2):130-6. PubMed ID: 18622676
    [Abstract] [Full Text] [Related]

  • 20. Assessment of micafungin regimens by pharmacokinetic-pharmacodynamic analysis: a dosing strategy for Aspergillus infections.
    Ikawa K, Nomura K, Morikawa N, Ikeda K, Taniwaki M.
    J Antimicrob Chemother; 2009 Oct; 64(4):840-4. PubMed ID: 19700475
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.